CT83 (cancer/testis antigen 83) is also called as CXorf61 and codes for a cancer/testis antigen that is located on human chromosome Xq22. The gene has 556 bp, including an open reading frame that has 113 amino acids. It is also termed as kita-kyushu lung cancer antigen 1 (KK-LC-1). CT83 is expressed in testis.
Synonyms: CXorf61; FLJ20611; FLJ22913; KK-LC-1
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: CT83 (cancer/testis antigen 83) / CXorf61 has the ability to interact with tumor-specific cytotoxic T-cell lymphocytes in lung cancer cells and can be considered as a potential immunotherapy target. It also acts as a target for T cell based immunotherapy of triple-negative breast cancer.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC